Presentation is loading. Please wait.

Presentation is loading. Please wait.

Acinetobacter Infections in a Hospital Setting Gonzalo Bearman MD, MPH Assistant Professor of Medicine, Epidemiology and Community Health Associate Hospital.

Similar presentations


Presentation on theme: "Acinetobacter Infections in a Hospital Setting Gonzalo Bearman MD, MPH Assistant Professor of Medicine, Epidemiology and Community Health Associate Hospital."— Presentation transcript:

1 Acinetobacter Infections in a Hospital Setting Gonzalo Bearman MD, MPH Assistant Professor of Medicine, Epidemiology and Community Health Associate Hospital Epidemiologist Virginia Commonwealth University University Medical Center-Medical Grand Rounds Las Vegas, Nevada February 17, 2006

2 Epidemiology & Prevention of Acinetobacter Infections Microbiology Infections: –Scope of the problem –Impact –Outbreaks Reservoirs of Acinetobacter in the hospital –Colonization HCWs, patients, environment –Cross transmission Treatment of Acinetobacter infections Limiting cross transmission of Acinetobacter –Infection control Summary

3 Acinetobacter Akinetos, Greek adjective, unable to move Bakterion, Greek noun, rod Nonmotile rod Brisou and Prévot, 1954

4 Microbiology Oxidase negative Nitrate negative Catalase positive Nonfermentative Nonmotile Strictly aerobic Gram negative coccobacillus –Sometimes difficult to decolorize Frequently arranged in pairs Bergogne-Bérézin E, Towner KJ. Clin Microbiol Rev 1996;9:

5 Microbiology Ubiquitous: –Widely distributed in nature (soil, water, food, sewage) & the hospital environment Survive on moist & dry surfaces 32 species –>2/3 of Acinetobacter infections are due to A. baumanii Highly antibiotic resistant –Numerous mechanisms of resistance to β-lactams described in A. baumanii –15 aminoglycoside-modifying enzymes described –Quinolone resistance due to mutations in DNA gyrase

6 Hospital acquired Acinetobacter infections

7 Major infections due to Acinetobacter Ventilator-associated pneumonia Urinary tract Bloodstream infection infection Secondary meningitis Skin/wound infections Endocarditis CAPD-associated peritonitis Ventriculitis

8 Acinetobacter Ventilator- Associated Pneumonia Acinetobacter accounts for 5-25% of all cases of VAP Risk factors: –Advanced age –Chronic lung disease –Immunosuppression –Surgery –Use of antimicrobial agents –Invasive devices –Prolonged ICU stay

9 Acinetobacter Bloodstream Infection Most common source is respiratory tract infection Predisposing factors: –Malignancy –Trauma –Burns –Surgical wound infections –Neonates Low birth weight Need for mechanical ventilation

10 Nosocomial Bloodstream Infections RankPathogen BSI/10,000 admissionsPercent 1Coagulase-negative Staph % 2S. aureus10.317% 3Enterococci4.812% 4Candida spp4.68% 5E. coli2.86% 6Klebsiella2.45% 7Ps. aeruginosa2.14% 7Enterobacter1.94% 8Serratia1.72% 9Acinetobacter baumanii0.61% 49 US centers N= 24,179 Wisplinghoff H, Edmond MB et al. Clin Infect Dis Aug 1;39(3):309-17

11 SCOPE Acinetobacter Nosocomial BSI Incidence = 0.6/10,000 admissions Accounts for 1.3% of all nosocomial BSI Accounts for 1.6% of all nosocomial BSI in the ICU setting Crude mortality: –Overall 34% –ICU 43% Wisplinghoff H, Edmond MB et al. Clin Infect Dis Aug 1;39(3): Despite the low incidence, the mortality is high

12 Time to Nosocomial BSI Wisplinghoff H, Edmond MB et al. Clin Infect Dis Aug 1;39(3): Acinetobacter BSI tends to be a late onset, hospital acquired phenomenon

13 Source of A. baumanii Nosocomial Bloodstream Infection Respiratory tract 71% Central venous line 8% Abdominal infection 19% N=37 Garcia-Garmendia J-L et al. Clin Infect Dis 2001;33: The respiratory tract is an important reservoir for Acinetobacter bloodstream infections

14 Inflammatory Response to A. baumanii Nosocomial Bloodstream Infection Sepsis 55% Severe sepsis 21% Septic shock 24% N=42 Garcia-Garmendia J-L et al. Clin Infect Dis 2001;33:

15 Independent Predictors of A. baumanii Nosocomial Bloodstream Infection Risk factors A. baumaniil (n=42) Other gram negative (n=35) Odds Ratio (CI 95 ) Immunosuppression 24%3%3.0 ( ) Unscheduled admission 86%51%3.3 ( ) Respiratory failure at admission 60%14%2.9 ( ) Previous antibiotic therapy 64%13%2.3 ( ) Previous sepsis in ICU 79%17%4.4 ( ) Invasive procedure index* (mean value) ( ) No. of invasive procedure-days/number of days in ICU prior to BSI Garcia-Garmendia J-L et al. Clin Infect Dis 2001;33:

16 Acinetobacter Meningitis Most cases are hospital-acquired Often associated with neurosurgical procedures Risk factors: –Ventriculostomy –Heavy use of antibiotics in the neurosurgical ICU

17 Impact of Acinetobacter Infection in the ICU

18 Impact of Acinetobacter Infection in the ICU: historical cohort study OutcomeGroupAny infectionPneumonia Mortality Cases58%70% Controls15%17% Attributable mortality43%53% Risk ratio for death4.0 (CI )4.0 (CI ) Length of stay (median) Cases23 days Controls10 days Excess LOS13 days Garcia-Garmendia JL et al. Crit Care Med 1999;27: patients with Acinetobacter infection matched 1:1 to patients without infection Controls were matched to cases on: age (+6yrs), APACHE II (+ 4 points), admission date, principal diagnosis at ICU admission, LOS at least as long as case until isolation of AB, requirement for mechanical ventilation

19 Impact of Acinetobacter Bloodstream Infection in the ICU OutcomeGroupBloodstream infection Mortality Cases42% Controls34% Attributable mortality8% Risk ratio for death1.0 (CI ) Length of ICU stay (median) Cases25 days Controls20 days Excess ICU LOS5 days Blot S. Intensive Care Med 2003;29: Historical cohort study of 45 patients with Acinetobacter bloodstream infection matched 1:2 to patients without infection Controls were matched to cases on: APACHE II (+ 2 points), principal diagnosis at ICU admission, LOS at least as long as case until bacteremia

20 Impact of A. baumanii Ventilator- Associated Pneumonia in the ICU OutcomeGroupAllImipenem (R) Mortality Cases40%44% Controls28%24% Attributable mortality 12% P=NS 20% P=NS Length of ICU stay (median) Cases35 days Controls37 days Excess ICU LOS -2 days P=NS Garnacho J et al. Crit Care Med 2003;10: Historical cohort study of 60 patients with A. baumanii VAP matched 1:1 to patients without A. baumanii infection Controls were matched to cases on: age, APACHE II score, admission date, principal diagnosis, LOS at least as long as case until onset of pneumonia, chronic health status

21 Acinetobacter outbreaks Detection of Acinetobacter Infections Consider: organ site, genetic typing, hospital location Common source outbreak with respiratory site predominance Common source outbreak without respiratory site predominance Respiratory site outbreaks without an identified common source Non- respiratory site outbreaks without an identified common source Villegas M, Hartstein A. Infect Control Hosp Epidemiol. 2003;24:

22 Acinetobacter outbreaks Villegas M, Hartstein A. Infect Control Hosp Epidemiol. 2003;24: Extensive Literature review and summary of 51 Acinetobacter outbreaks CharacteristicNumber of reportsComment Publication year: The majority of the reports occurred over the last 9 years ICU setting percent of reports were exclusively or predominantly ICU related outbreaks or clusters Patient age category: Adult Pediatric percent of all outbreaks were in an adult population

23 Acinetobacter outbreaks Villegas M, Hartstein A. Infect Control Hosp Epidemiol. 2003;24: Studies with a focus on antimicrobial resistance Antimicrobial class Number of studies reporting new or increasing resistance Aminoglycosides6 Multiple classes14 Carbapenems3

24 Acinetobacter outbreaks Studies with a common source outbreak with a respiratory cluster: Clonal transmission confirmed by PFGE or PCR-based typing Setting:Common Source: Adult ICU Adult,neonatal and pediatric ICU Adult mixed ICU Surgical and medical ICU Adult ICU Neonatal ICU Adult mixed ICU Ventilator spirometers Reusable ventilator circuits In line temperature monitor probes Ventilator temperature probes ‘Y’ piece of ventilator Suction catheter and bottle Peak flow meter Villegas M, Hartstein A. Infect Control Hosp Epidemiol. 2003;24:

25 Acinetobacter outbreaks Studies with a common source outbreak without a respiratory cluster: Clonal transmission confirmed by PFGE or PCR-based typing Setting:Common Source: Medical Wards Medical ICU Cardiac Catheterization Lab Dialysis center Burn unit Hospital wide Pediatric oncology war Bedside humidifiers Warming bath water Hospital prepared distilled water Heparinized saline solution Patient mattresses Feather pillows Water taps in staff room with mesh aerators Villegas M, Hartstein A. Infect Control Hosp Epidemiol. 2003;24:

26 Acinetobacter outbreaks Studies with a predominant respiratory site outbreak without an identifiable common source 8 Studies with a predominant non-respiratory site outbreak without an identifiable common source SettingsMedical ICU Surgical ICU Shock-Trauma ICU Medical Wards Nursery Mixed Medical/Surgical ICU Burn and Plastic Surgery Wards Villegas M, Hartstein A. Infect Control Hosp Epidemiol. 2003;24:

27 Reservoirs of Acinetobacter: Where do these organisms reside?

28 Environmental Contamination with Acinetobacter Bed rails Bedside tables Ventilators Infusion pumps Mattresses Pillows Air humidifers Patient monitors X-ray view boxes Curtain rails Curtains Equipment carts Sinks Ventilator circuits Floor mops

29 Factors Promoting Transmission of of Acinetobacter in the ICU Long survival time on inanimate surfaces –In vitro survival time 329 days (Wagenvoort JHT, Joosten EJAJ. J Hosp Infect 2002;52: ) –11 days survival on Formica, 12 days on stainless steel (Webster C et al. Infect Control Hosp Epidemiol 2000;21:246) –Up to 4 months on dry surfaces (Wendt C et al. J Clin Microbiol 1997;35: ) Extensive environmental contamination Highly antibiotic resistant High proportion of colonized patients Frequent contamination of the hands of healthcare workers

30 Acinetobacter Transmission in the Hospital Setting Direct or indirect contact –Contaminated hands of healthcare workers Airborne transmission via aerosol production (e.g., hydrotherapy) may occur Simor AE et al. Infect Control Hosp Epidemiol 2002;23:

31 Evidence for Airborne Transmission of Acinetobacter Sedimentation plates placed in 7 patients’ rooms with respiratory infection or colonization Brooks SE et al. Infect Control Hosp Epidemiol 2000;21:304. % of plates growing Acinetobacter

32 Acinetobacter spp Skin Colonization Body site Hospitalized patients (n=40) Healthy controls (n=40) Forehead33%13% Ear35%7% Nose33%8% Throat15%0% Axilla33%3% Hand33%20% Groin38%13% Perineum20%3% Toe web40%8% Any site75%42.5% Seifert H et al. J Clin Microbiol 1997; 35: A. baumanii isolated from 2 patients & 1 control only

33 Acinetobacter Transmission in the Hospital Setting Colonization of Healthcare Workers Outbreak of multidrug resistant A. baumanii in a Dutch ICU involving 66 patients with an epidemic strain Nursing staff were cultured (nares & axilla, same swab) –15 nurses found to harbor epidemic strain –All were culture negative when re-cultured (nose, throat, axilla, perineum) Wagenvoort JHT et al. Eur J Clin Microbiol Infect Dis 2002;21:

34 Hand Contamination in HCWs Bauer TM et al. J Hosp Infect 1990;15: % of HCWs (n=328) with hand contamination

35 Opportunities for cross transmission are multiple

36 Treatment of Acinetobacter infections

37 Acinetobacter Susceptibility, US, % susceptible TSN Database. Increasing rate of antibiotic resistance

38 Antibiotic Resistance Community vs. Hospital Acquisition Comparison of A. baumanii isolates obtained from the hands of homemakers to isolates obtained from 2 US hospitals –23/222 (10.4%) homemakers had A.baumanii isolated from hands Antimicrobial resistance Hospital (n=101) Community (n=23)Odds Ratio (CI 95 ) 3 rd generation cephalosporins 88%9%78 (15-553) Carbapenems 64%4%39 (5-811) Aminoglycosides 43%4%16 (2-337) Multidrug resistant* 37%0%Not calculable *3 rd gen. cephalosporins + carbapenem + aminoglycoside Zeana C. Infect Control Hosp Epidemiol 2003;24:

39 Polymyxin antibiotics A group of polypeptide antibiotics that consists of 5 chemically different compounds (polymyxins A E). Only polymyxin B and polymyxin E (colistin) have been used in clinically. Intravenous colistin should be considered for the treatment of infections caused by gram-negative bacteria resistant to other available antimicrobial agents, confirmed by appropriate in vitro susceptibility testing

40 Polymyxin antibiotics: History –Used extensively worldwide in topical otic and ophthalmic solutions for decades –Intravenous Colistin was initially used in Japan and in Europe during the 1950s, and in the United States in the form of colistimethate sodium in 1959 –The intravenous formulations of colistin and polymyxin B were gradually abandoned in most parts of the world in the early 1980s because of the reported high incidence of nephrotoxicity –Colistin was mainly restricted during the past 2 decades for the treatment of lung infections due to multidrug-resistant (MDR), gram-negative bacteria in patients with cystic fibrosis

41 Polymyxin antibiotics colistin sulfate: oral, used for bowel decontamination colistimethate sodium: (also called colistin methanesulfate, pentasodium colistimethanesulfate, and colistin sulfonyl methate)- Intravenous formulation Clinical Infectious Diseases 2005;40:

42 Polymyxin antibiotics Mechanism of action: –Target: Bacterial cell membrane Colistin binding with the bacterial membrane occurs through electrostatic interactions between the cationic polypeptide (colistin) and anionic lipopolysaccharide (LPS) molecules in the outer membrane of the gram-negative bacteria –leads to a derangement of the cell membrane –The result of this is an increase in the permeability of the cell envelope, leakage of cell contents, and, subsequently, cell death.

43 Polymyxin antibiotics Clinical Infectious Diseases 2005;40: Sections of a Pseudomonas aeruginosa strain showing the alterations in the cell following the administration of polymyxin B (25 g/mL for 30 min) and colistin methanesulfate (250 g/mL for 30 min). A: untreated cell; B: cell treated with polymyxin C: cell treated with colistin methanesulfate; D: cell treated with polymyxin B at higher magnification.= 0.1 m

44 Polymyxin antibiotics Development of Resistance –Resistance to colistin occurs through mutation or adaptation mechanisms –Almost complete cross-resistance exists between colistin and polymyxin B

45 Polymyxin antibiotics Important pharmacokinetic parameters –Colistin sulfate and colistimethate sodium are not absorbed by the gastrointestinal tract with oral administration –Primary route of excretion is through glomerular filtration –Experimental studies have shown that colistin is tightly bound to membrane lipids of tissues, including liver, lung, kidney, brain, heart, and muscles –Concentration of colistin in the CSF is 25% of the serum concentration

46 Polymyxin antibiotics Spectrum of activity –Most gram-negative aerobic bacilli: Acinetobacter species, P. aeruginosa, Klebsiella species, Enterobacter species, Escherichia coli, Salmonella species, Shigella species, Citrobacter species, Yersinia pseudotuberculosis, Morganella morganii, and Haemophilus influenzae –No activity against: Pseudomonas mallei, Burkholderia cepacia, Proteus species, Providencia species, Serratia species, Edwardsiella species, and Brucella

47 Polymyxin antibiotics Susceptibility testing: –Disk diffusion- Colistin Disk diffusion method that uses a 10-ug colistin sulfate disk Isolates is susceptible if the zone of inhibition is >11 mm –Dilution method- colistimethate sodium The MIC break point for susceptibility is <4 mg/L If the MIC is >8 mg/L, the isolate should be considered resistant

48 Polymyxin antibiotics RouteDosage Intravenous2.5-5 mg/kg (31,250-62,500 IU/kg) per day, divided into 2-4 equal doses (1 mg of colistin equals 12,500 IU). Modification of the total daily dose is required in the presence of renal impairment IntramuscularSame as IV Inhalation40 mg (500,000 IU) every 12 h for patients 40 kg For recurrent pulmonary infections, the dose can be increased to 160 mg (2 million IU) every 8 h Intraventricular/ intrathecal (not FDA approved) Limited data based on case reports Intrathecal dosage ranged from 3.2 mg (40,000 IU) to 10 mg (125,000 IU) given once per day Intraventricular dosage ranged from 10 mg (125,000 IU) to 20 mg (250,000 IU) per day (divided into 2 doses)

49 Polymixin adverse effects NeurotoxicityComments Dizziness Weakness Paresthesias-most common Vertigo Visual disturbances Confusion Ataxia Neuromuscular blockade- respiratory failure 7 % incidence of Colistin associated neurotoxicity 29% incidence in patients with Cystic Fibrosis Toxicity is dose dependent Toxicity is reversible upon discontinuation of medication

50 Polymixin adverse effects Nephrotoxicity The majority of nephrotoxic events are reversible 1970’s- incidence of nephrotoxicity was 20.2% More recent studies- incidence of nephrotoxicity ranged from 8%-18%. Lower incidence of Nephrotoxicity at present: –Greater supportive treatment to critically ill patients –Close monitoring of renal function –Avoidance of co-administered nephrotoxic agents –Older formulations of Colistin contained a greater proportion of colistin sulfate (greater nephrotoxicity)

51 Limiting the cross transmission of Acinetobacter

52 Preventing Acinetobacter Transmission in the ICU General Measures Hand hygiene –Use of alcohol-based hand sanitizers Contact precautions –Gowns/gloves –Dedicate non-critical devices to patient room Environmental decontamination Prudent use of antibiotics Avoidance of transfer of patients to Burn Unit from other ICUs

53 Preventing Acinetobacter Transmission in the ICU Outbreak Interventions Hand cultures Surveillance cultures Environmental cultures following terminal disinfection to document cleaning efficacy Cohorting Ask laboratory to save all isolates for molecular typing Healthcare worker education If transmission continues despite above interventions, closure of unit to new admissions

54 Efficacy of Handwashing Agents against Acinetobacter Experimental study to access removal of A. baumanii from the hands of volunteers –Fingertips inoculated with with either 10 3 CFU (light contamination) or 10 6 CFU (heavy contamination) Agent Removal Rate Light contaminationHeavy contamination Plain soap 99.97%92.40% 70% Ethyl alcohol 99.98%98.94% 10% Povidone-iodine 99.98%98.48% 4% Chlorhexidine 99.81%91.39% Cardoso CL et al. Am J Infect Control 1999;27:

55 In Vitro Activity of Alcohol Hand Rubs Alcohol(s)Other agents Log  60% isopropyl, 0.05% phenoxyethyl % ethyl, 27% isopropyl, 1% benzyl % ethyl0.3% triclosan0.3 30% I-propanol, 45% isopropyl0.2% mecetronium3.2 60% isopropyl0.5% chlorhexidine>5.0 70% isopropyl0.5% chlorhexidine, 0.45% H 2 O 2 >5.0 89% isopropyl/ethyl0.1% chlorhexidine>5.0 40% I-propanol, 30% isopropyl0.1% octenidine>5.0 55% isopropyl0.5% triclosan>5.0 Rochon-Edouard S et al. Am J Infect Control 2004;32: Each agent diluted 1/10 & tested against a strain of A. baumanii resistant to 3 rd generation cephalosporins

56 Chlorhexidine Resistance in Acinetobacter Biocide resistance in gram-negative organisms is mainly intrinsic & chromosomal (plasmid mediated in gram-positive organism) 10 strains of A. baumanii tested for chlorhexidine susceptibility –Median MIC 32 mg/L –Median MBC 32 mg/mL –Chlorhexidine resistance increased with increased antibiotic resistance Kõljalg S et al. J Hosp Infect 2002;51:

57 Summary Although commonly found on the skin of healthy humans, Acinetobacter plays the role of an opportunistic pathogen in the critically ill patient High level of antibiotic resistance makes it well suited as a pathogen in areas with high use of antibiotics (e.g., ICU setting) Control requires good hand hygiene, barrier precautions & environmental decontamination –Alcohol-based products containing chlorhexidine should be considered the hand hygiene agents of choice


Download ppt "Acinetobacter Infections in a Hospital Setting Gonzalo Bearman MD, MPH Assistant Professor of Medicine, Epidemiology and Community Health Associate Hospital."

Similar presentations


Ads by Google